Market Access Policy in Focus: What’s new with CMS drug price negotiation,... Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.
Market Access Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al... Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.
Market Access Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go... Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.
Market Access Smoothing a contract pathway through uncertainty: In convers... Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.
Market Access FH25: Commercialising Health Tech and Deeptech, with Pilar F... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
News Medable, Tufts CSDD value AI gain at $21m net per programme New analysis from Tufts CSDD and Medable shows AI agent value to oncological drug development programmes at up to $21m each.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.